215 related articles for article (PubMed ID: 15674108)
1. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study.
González-Lama Y; Abreu L; Vera MI; Pastrana M; Tabernero S; Revilla J; Durán JG; Escartin P
Inflamm Bowel Dis; 2005 Jan; 11(1):8-15. PubMed ID: 15674108
[TBL] [Abstract][Full Text] [Related]
2. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience.
Topstad DR; Panaccione R; Heine JA; Johnson DR; MacLean AR; Buie WD
Dis Colon Rectum; 2003 May; 46(5):577-83. PubMed ID: 12792431
[TBL] [Abstract][Full Text] [Related]
3. Remicade does not abolish the need for surgery in fistulizing Crohn's disease.
Poritz LS; Rowe WA; Koltun WA
Dis Colon Rectum; 2002 Jun; 45(6):771-5. PubMed ID: 12072629
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
5. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.
Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R
Aliment Pharmacol Ther; 2002 Jun; 16(6):1117-24. PubMed ID: 12030953
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus for Crohn's disease.
Ruddock B
Issues Emerg Health Technol; 2006 Sep; (88):1-4. PubMed ID: 16981314
[TBL] [Abstract][Full Text] [Related]
7. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
Ochsenkühn T; Göke B; Sackmann M
Am J Gastroenterol; 2002 Aug; 97(8):2022-5. PubMed ID: 12190171
[TBL] [Abstract][Full Text] [Related]
8. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.
Schröder O; Blumenstein I; Schulte-Bockholt A; Stein J
Aliment Pharmacol Ther; 2004 Feb; 19(3):295-301. PubMed ID: 14984376
[TBL] [Abstract][Full Text] [Related]
9. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease.
Sandborn WJ
Am J Gastroenterol; 1997 May; 92(5):876-9. PubMed ID: 9149205
[TBL] [Abstract][Full Text] [Related]
10. Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial.
Hart AL; Plamondon S; Kamm MA
Inflamm Bowel Dis; 2007 Mar; 13(3):245-53. PubMed ID: 17206671
[TBL] [Abstract][Full Text] [Related]
11. Infliximab in treatment of Crohn's disease: the Milan experience.
Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae.
Lowry PW; Weaver AL; Tremaine WJ; Sandborn WJ
Inflamm Bowel Dis; 1999 Nov; 5(4):239-45. PubMed ID: 10579116
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.
Egan LJ; Sandborn WJ; Tremaine WJ
Am J Gastroenterol; 1998 Mar; 93(3):442-8. PubMed ID: 9517654
[TBL] [Abstract][Full Text] [Related]
15. Predictors of response to infliximab in patients with fistulizing Crohn's disease.
Luna-Chadid M; Pérez Calle JL; Mendoza JL; Vera MI; Bermejo AF; Sánchez F; López San Román A; Froilán C; González-Lara V; García-Paredes J; Fernández-Blanco I; Abreu L; Casis B; Solís Herruzo JA; Gisbert JP; Maté Jiménez J
Rev Esp Enferm Dig; 2004 Jun; 96(6):379-81; 382-4. PubMed ID: 15230667
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
Kinney T; Rawlins M; Kozarek R; France R; Patterson D
Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
[TBL] [Abstract][Full Text] [Related]
17. Long-term oral tacrolimus in refractory to infliximab fistulizing Crohn's disease: comments from Spanish experience.
González Lama Y; Abreu LE; Vera MI; de la Revilla J; Fernandez-Puga N; Escartin P
Gastroenterology; 2004 Mar; 126(3):942-3; author reply 943. PubMed ID: 14988864
[No Abstract] [Full Text] [Related]
18. Transcending conventional therapies: the role of biologic and other novel therapies.
Sandborn WJ
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease.
Yang BL; Chen YG; Gu YF; Chen HJ; Sun GD; Zhu P; Shao WJ
World J Gastroenterol; 2015 Feb; 21(8):2475-82. PubMed ID: 25741157
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study.
Sands BE; Blank MA; Patel K; van Deventer SJ;
Clin Gastroenterol Hepatol; 2004 Oct; 2(10):912-20. PubMed ID: 15476155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
